prikaz prve stranice dokumenta Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)
  Preuzmi
PDF 1.05 MB
Stručni rad - Stručni rad
Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)
Journal of the European Academy of Dermatology and Venereology, 36 (2022), 10; 1689-1704. https://doi.org/10.1111/jdv.18220
Borradori, L.; Van Beek, N.; Feliciani, C.; Tedbirt, B.; Antiga, E.; Bergman, R.; Böckle, B. C.; Caproni, M.; Caux, F.; Chandran, N.S.; Cianchini, G.; Daneshpazhooh, M.; De, D.; Didona, D.; Di Zenzo, G. M.; Dmochowski, M.; Drenovska, K.; Ehrchen, J.; Goebeler, M.; Groves, R.; Günther, C.; Horvath, B.; Hertl, M.; Hofmann, S.; Ioannides, D.; Itzlinger‐Monshi, B.; Jedličková, J.; Kowalewski, C.; Kridin, K.; Lim, Y. L.; Marinović, Branka; Marzano, A. V.; Mascaro, J.‐M.; Meijer, J.M.; Murrell, D.; Patsatsi, K.; Pincelli, C.; Prost, C.; Rappersberger, K.; Sárdy, M.; Setterfield, J.; Shahid, M.; Sprecher, E.; Tasanen, K.; Uzun, S.; Vassileva, S.; Vestergaard, K.; Vorobyev, A.; Vujic, I.; Wang, G.; Wozniak, K.; Yayli, S.; Zambruno, G.; Zillikens, D.; Schmidt, E.; Joly, P. Više autora...

Citirajte ovaj rad

Borradori, L., Van Beek, N., Feliciani, C., Tedbirt, B., Antiga, E., Bergman, R. ... Joly, P. (2022). Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). Journal of the European Academy of Dermatology and Venereology, 36. (10), 1689-1704. doi: 10.1111/jdv.18220

Borradori, L., et al. "Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)." Journal of the European Academy of Dermatology and Venereology, vol. 36, br. 10, 2022, str. 1689-1704. https://doi.org/10.1111/jdv.18220

Borradori, L., N. Van Beek, C. Feliciani, B. Tedbirt, E. Antiga, R. Bergman, B. C. Böckle, et al. "Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)." Journal of the European Academy of Dermatology and Venereology 36, br. 10 (2022): 1689-1704. https://doi.org/10.1111/jdv.18220

Borradori, L., et al. (2022) 'Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)', Journal of the European Academy of Dermatology and Venereology, 36(10), str. 1689-1704. doi: 10.1111/jdv.18220

Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, i sur.. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). Journal of the European Academy of Dermatology and Venereology [Internet]. 10.2022. [pristupljeno 30.09.2024.];36(10):1689-1704. doi: 10.1111/jdv.18220

L. Borradori, et al., "Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)", Journal of the European Academy of Dermatology and Venereology, vol. 36, br. 10, str. 1689-1704, Listopad 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:834756. [Citirano: 30.09.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:834756
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)
AutorL. Borradori
AutorN. Van Beek
AutorC. Feliciani
AutorB. Tedbirt
AutorE. Antiga
AutorR. Bergman
AutorB. C. Böckle
AutorM. Caproni
AutorF. Caux
AutorN.S. Chandran
AutorG. Cianchini
AutorM. Daneshpazhooh
AutorD. De
AutorD. Didona
AutorG. M. Di Zenzo
AutorM. Dmochowski
AutorK. Drenovska
AutorJ. Ehrchen
AutorM. Goebeler
AutorR. Groves
AutorC. Günther
AutorB. Horvath
AutorM. Hertl
AutorS. Hofmann
AutorD. Ioannides
AutorB. Itzlinger‐Monshi
AutorJ. Jedličková
AutorC. Kowalewski
AutorK. Kridin
AutorY. L. Lim
AutorBranka Marinović
AutorA. V. Marzano
AutorJ.‐M. Mascaro
AutorJ.M. Meijer
AutorD. Murrell
AutorK. Patsatsi
AutorC. Pincelli
AutorC. Prost
AutorK. Rappersberger
AutorM. Sárdy
AutorJ. Setterfield
AutorM. Shahid
AutorE. Sprecher
AutorK. Tasanen
AutorS. Uzun
AutorS. Vassileva
AutorK. Vestergaard
AutorA. Vorobyev
AutorI. Vujic
AutorG. Wang
AutorK. Wozniak
AutorS. Yayli
AutorG. Zambruno
AutorD. Zillikens
AutorE. Schmidt
AutorP. Joly
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA DERMATOVENEROLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Dermatovenerologija
Sažetak (engleski)
Background: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo-like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life. ----- Objectives and methodology: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence-based or rely on expert opinion. The degree of consent among all task force members was included. ----- Results: Treatment depends on the severity of BP and patients' comorbidities. High-potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B-cell-depleting therapy and intravenous immunoglobulins may be considered in treatment-resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations. ----- Conclusions: The guidelines for the management of BP were updated. They summarize evidence- and expert-based recommendations useful in clinical practice.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeStručni rad - Stručni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of the European Academy of Dermatology and Venereology
Brojčani podacivol. 36, br. 10, str. 1689-1704
p-ISSN0926-9959
e-ISSN1468-3083
DOIhttps://doi.org/10.1111/jdv.18220
URN:NBNurn:nbn:hr:105:834756
Datum objave publikacije2022-10
URL dokumentahttps://onlinelibrary.wiley.com/doi/10.1111/jdv.18220
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2022-11-16 12:32:05